Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

NCT03336580 is registered in ClinicalTrials.gov with Prothena Biosciences Limited as lead sponsor.

NCT NCT03336580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03336580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Lead sponsor
Prothena Biosciences Limited
Phase
Phase 1
Overall status
Terminated
Start date
April 5, 2018
Completion date
July 23, 2020
Enrollment
21 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidogenic transthyretin (attr) amyloidosis